WO2023141631A3 - Formulations and active pharmaceutical ingredients for treating ophthalmic and systemic diseases - Google Patents

Formulations and active pharmaceutical ingredients for treating ophthalmic and systemic diseases Download PDF

Info

Publication number
WO2023141631A3
WO2023141631A3 PCT/US2023/061098 US2023061098W WO2023141631A3 WO 2023141631 A3 WO2023141631 A3 WO 2023141631A3 US 2023061098 W US2023061098 W US 2023061098W WO 2023141631 A3 WO2023141631 A3 WO 2023141631A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
blocker
combination therapy
formulations
treating ophthalmic
Prior art date
Application number
PCT/US2023/061098
Other languages
French (fr)
Other versions
WO2023141631A2 (en
Inventor
Malik Y. Kahook
Original Assignee
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Colorado, A Body Corporate filed Critical The Regents Of The University Of Colorado, A Body Corporate
Publication of WO2023141631A2 publication Critical patent/WO2023141631A2/en
Publication of WO2023141631A3 publication Critical patent/WO2023141631A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Improved methods for treating ophthalmic disorders, particularly those associated with ocular hypertension and glaucoma. Methods of treatment and pharmaceutical compositions for treatment of ophthalmic disorders employing one or more beta-adrenergic blocking agent (beta-blocker) or one or more carbonic anhydrate inhibitor (CAI) as active ingredients, where the one or more active ingredient is formulated for delivery to the oral mucosa. Also provided is combination therapy and pharmaceutical compositions useful for such therapy employing one or more beta-adrenergic blocking agent (beta-blocker) and one or more carbonic anhydrase inhibitor (CAI). This combination therapy provides significant therapeutic improvement compared to the use of a beta-blocker or carbonic anhydrase inhibitor alone. Preferably the active ingredients for combination therapy are administered in a solid dosage form suitable for oral mucosal delivery, e.g., in the form of a rapidly disintegrable tablet.
PCT/US2023/061098 2022-01-24 2023-01-23 Formulations and active pharmaceutical ingredients for treating ophthalmic and systemic diseases WO2023141631A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263302384P 2022-01-24 2022-01-24
US63/302,384 2022-01-24

Publications (2)

Publication Number Publication Date
WO2023141631A2 WO2023141631A2 (en) 2023-07-27
WO2023141631A3 true WO2023141631A3 (en) 2023-09-28

Family

ID=87349208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/061098 WO2023141631A2 (en) 2022-01-24 2023-01-23 Formulations and active pharmaceutical ingredients for treating ophthalmic and systemic diseases

Country Status (1)

Country Link
WO (1) WO2023141631A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283065A (en) * 1989-09-21 1994-02-01 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
WO2019210215A1 (en) * 2018-04-26 2019-10-31 Graybug Vision, Inc. Drugs to treat ocular disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283065A (en) * 1989-09-21 1994-02-01 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
WO2019210215A1 (en) * 2018-04-26 2019-10-31 Graybug Vision, Inc. Drugs to treat ocular disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOODA RAKESH, TRIPATHI MOHIT, KAPOOR KIRAN: "A Review on Oral Mucosal Drug Delivery System", THE PHARMA INNOVATION, THE PHARMA INNOVATION, NEW DELHI, vol. 1, no. 1, Part A, 1 March 2012 (2012-03-01), New Delhi, pages 14, XP093096234 *

Also Published As

Publication number Publication date
WO2023141631A2 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
US11938166B2 (en) Methods and compositions for treating mucosal tissue disorders
US6919348B2 (en) Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
RU2292208C2 (en) New combination of anti-histamine agents having no sedative action with compounds effecting to leukotrien action for rhinitis/conjunctivitis treatment
JP2001517639A (en) Use of a combination comprising a non-sedating antihistamine and an α-adrenergic agonist for the topical treatment of rhinitis / conjunctivitis and cold, cold-like and / or epidemic cold symptoms
KR20020016832A (en) Compositions and methods comprising morphine gluconate
JP2009137971A (en) Medicine and medicinal kit
JP4521117B2 (en) Medications for treating migraine, cluster headache, tension headache, headache associated with vascular disease, tinnitus or muscular headache
JP2001510157A (en) Peripherally acting anti-pruritus opiates
EP1503763B1 (en) Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US20030082249A1 (en) Compositions containing capsaicin and its derivatives, and their use in treating mucositis
WO2023141631A3 (en) Formulations and active pharmaceutical ingredients for treating ophthalmic and systemic diseases
JP2022508236A (en) Montelukast for the treatment of erosive osteoarthritis
CA2185883C (en) The use of dimeticone as a transport and carrier system and/or drug delivery system
JP2017502089A (en) Migraine treatment
JP2001526217A (en) Novel use of local anesthetics for vascular headache
WO2003063879A1 (en) Remedies for glaucoma comprising bunazosin and prostaglandins
JP2002161032A (en) Composition applied to mucous membrane
JPWO2005058878A1 (en) Preventive and / or therapeutic agent for dysmenorrhea
CN114767630A (en) Medicine composition for treating allergic rhinitis and application thereof
NZ282805A (en) Use of dimethylpolysiloxane (dimeticone) as a carrier in medicaments
Doggrell Triamcinolone
Yosef et al. ACUTE RHINOSINUSITIS: NASONEX AS ADJUNCTIVE THERAPY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23743998

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE